<DOC>
	<DOCNO>NCT01902524</DOCNO>
	<brief_summary>The purpose study confirm effectiveness safety fentanyl transdermal patch Durogesic® D-Trans treatment chronic pain participant chronic non-cancer pain .</brief_summary>
	<brief_title>Efficacy Safety Study Fentanyl Transdermal Patch Treatment Chronic Pain</brief_title>
	<detailed_description>This trial Phase 4 , prospective , open-label ( mean research physician study participant know medication administer ) study fentanyl transdermal patch-type system ( TTS ) Durogesic® D-Trans patient non-cancer pain . The patch design systematically release adsorbed fentanyl percutaneously , constant rate three day ( 72 hour ) . The study conduct 12 week . The efficacy safety evaluate week 1 , week 4 , week 8 week 12 visit . All participant use patch least study . The drug efficacy evaluate percent change pain intensity treatment improvement follow activity : daily life , walk , meal intake , mood regulation . The overall safety assess base adverse event reporting .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>spine relate extremity pain last 3 month longer pain Numeric Rating Scale ( NRS ) 4 high past 72 hour good overall health condition base medical history clinical laboratory test participant use appropriate contraception case childbearing potential study period . history hypersensitive reaction narcotic analgesic history narcotic abuse serious psychotic disorder unable use transdermal analgesic due dermatological condition history CO2 retention ( e.g. , chronic obstructive pulmonary disease ) surgery area pain within 7 day prior initiation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Chronic Pain</keyword>
	<keyword>Fentanyl-TTS</keyword>
	<keyword>Fentanyl Patch</keyword>
	<keyword>Transdermal</keyword>
	<keyword>Non-cancer Pain</keyword>
</DOC>